Logo-ijhpm
Int J Health Policy Manag. 2021;10(4): 228-231. doi: 10.34172/ijhpm.2020.46
PMID: 32610794        PMCID: PMC8167272

Commentary

Deliberative Processes by Health Technology Assessment Agencies: A Reflection on Legitimacy, Values and Patient and Public Involvement Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe"

Mireille Goetghebeur 1 * ORCID, Marjo Cellier 2

Cited by CrossRef:

1- Wale J, Thomas S, Hamerlijnck D, Hollander R. Patients and public are important stakeholders in health technology assessment but the level of involvement is low – a call to action. Res Involv Engagem. 2021;7(1) [Crossref]
2- Cellier M. The Place and Importance of Patients in Deliberative Processes. Front Med Technol. 2021;3 [Crossref]
3- Kulembekova L, Hailey D, Kulzhanov M, Tabarov A, Georgiev S, Jaworzynska M, Yanakieva A, Kosherbayeva L. Stakeholders’ Involvement in Health Technology Assessment in Kazakhstan, Poland and Bulgaria. PPA. 2024;Volume 18:1009 [Crossref]
4- Wale J, Chandler D, Collyar D, Hamerlijnck D, Saldana R, Pemberton-Whitely Z. Can We Afford to Exclude Patients Throughout Health Technology Assessment?. Front Med Technol. 2022;3 [Crossref]